|Dr. Ignacio Faus M.B.A., Ph.D.||CEO & Director||N/A||N/A||N/A|
|Mr. Bruno Lafont M.Sc.||Co-Founder, COO & Director||N/A||N/A||N/A|
|Dr. Violaine Desort-Henin DVM||Medical Operation Director||N/A||N/A||N/A|
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
NFL Biosciences SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.